- Home
- Companies
- LimFlow, Inc.
- Articles
LimFlow, Inc. articles
Background. As the most advanced stage of peripheral arterial disease (PAD), chronic limb-threatening ischemia (CLTI) is associated with a high risk of lower-limb loss and mortality. Percutaneous deep vein arterialization (pDVA) is a promising new treatment alternative for CLTI patients who cannot be treated with conventional revascularization techniques. Our study objective was to explore the potential cost-effectiveness of treatment with the LimF
The increasing incidence of peripheral artery disease (PAD) is occurring globally as populations age and rates of diabetes, obesity, and renal disease increase.1-3 Although most of these patients have no symptoms, when the disease progresses to its most advanced form, chronic limb-threatening ischemia (CLTI), there is a significant risk for limb loss. Despite the fact that our revascularization options have improved over the last 20 years, a significant portion of patients with CLT
What interested you in LimFlow, and how did you get involved in the PROMISE I trial?
Dr. Clair: Practicing vascular surgery, where a number of patients are evaluated for chronic limb-threatening ischemia (CLTI), you are guaranteed to have patients who are not candidates for percutaneous or surgical revascularization. These patients often have arterial systems open or identifiable to the ankle, with little to no flow in the foot, or what has been term